دورية أكاديمية
Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
| العنوان: | Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors |
|---|---|
| المؤلفون: | Gibson, Amanda J.W., Box, Adrian, Dean, Michelle L., Elegbede, Anifat A., Hao, Desiree, Sangha, Randeep, Bebb, D. Gwyn |
| المساهمون: | Merck, Bristol-Myers Squibb, Novartis, Pfizer, AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company, AstraZeneca, Pfizer Canada |
| المصدر: | JTO Clinical and Research Reports ; volume 2, issue 4, page 100157 ; ISSN 2666-3643 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2021 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, Oncology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.jtocrr.2021.100157 |
| الإتاحة: | https://doi.org/10.1016/j.jtocrr.2021.100157Test https://api.elsevier.com/content/article/PII:S2666364321000163?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S2666364321000163?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.FEB34294 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jtocrr.2021.100157 |
|---|